Artios Pharma appointed three senior leaders to strengthen late-stage development capabilities: Roy W. Ware as Chief Manufacturing and Technology Officer, Caryn Barnett as VP of Clinical Operations, and Pablo Lee as VP of Medical Affairs. These appointments aim to accelerate the company's DDR-based oncology pipeline, particularly alnodesertib, toward potential commercialization and FDA approval.

Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeOne Medicines and Jazz Pharmaceuticals for commercialization rights.

Harmony Biosciences has achieved remarkable financial success with its narcolepsy drug Wakix, growing sales at 40% CAGR to nearly $870 million and achieving profitability with $186 million in net income. However, the stock has remained flat since its IPO due to concerns including a 2023 short-seller report alleging fraud, pending patent expiration in 2030, and intense competition from Jazz Pharmaceuticals' blockbuster treatments Xywav and Xyrem.

Zymeworks Inc. announced that its management will participate in multiple investor conferences in February and March 2026, including Citi's Virtual Oncology Leadership Summit, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Citizens Life Science Conference. The company continues to advance its portfolio of licensed healthcare assets and biotherapeutics pipeline.

Jazz Pharmaceuticals announced positive Phase 3 trial results for Ziihera (zanidatamab-hrii) in treating HER2-positive gastroesophageal adenocarcinoma. The triplet therapy combining Ziihera with tislelizumab and chemotherapy achieved a median overall survival of 26.4 months, the longest reported in a Phase 3 GEA trial, representing a 28% reduction in death risk. The doublet therapy also showed strong results with median OS of 24.4 months. Jazz shares rose 2.07% following the announcement.

Zymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk reduction) and overall survival (26.4 months median, representing a 7+ month improvement over trastuzumab). Zymeworks is eligible to receive up to $440 million in milestone payments from regulatory approvals across major markets.

Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.

Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.

Zymeworks, a clinical-stage biotechnology company, announced participation in upcoming investor conferences and highlighted its progress in developing biotherapeutics for cancer and other diseases, including the FDA-approved zanidatamab for biliary tract cancer.

Alkermes agreed to acquire Avadel Pharmaceuticals for up to $20 per share, valuing the deal at $2.1 billion. The acquisition includes the narcolepsy drug Lumryz and is expected to close in Q1 2026, with potential additional payment contingent on FDA approval.

Zymeworks will report its Q3 2025 financial results on November 6, 2025, and host a conference call to discuss financial performance and provide a corporate update.

The FDA approved Tecentriq and lurbinectedin as the first combination therapy for maintenance treatment of extensive-stage small cell lung cancer, reducing disease progression risk by 46% and death risk by 27% in clinical trials.